Product Overview

Mast P 100 by Odin Pharma standardizes 100mg/ml Drostanolone Propionate concentration within 10ml amber glass vial engineered for performance compound fulfillment. Short-ester propionate configuration provides rapid onset spanning 1-1.5 day half-life optimized for every-other-day administration protocols (300-700mg/week). Odin channels this potent presentation toward procurement networks prioritizing muscle hardening and definition within cutting cycle frameworks.​

Brand & Manufacturer Information

Odin Pharma configures production capacity around fast-acting DHT-derived injectables maintaining operational infrastructure optimized for warehouse-to-warehouse transit velocity and comprehensive batch traceability deployment. Manufacturing standardization emphasizes active pharmaceutical matrix quantitation consistency across 100mg/ml thresholds while integrating proprietary verification symbology. Wholesale partnerships leverage formulation potency metrics alongside perpetual replenishment cadence reliability critical for institutional distribution sustainability.​

Active Compound Information

Drostanolone Propionate (C23H36O3) manifests potent androgenic effects exhibiting anti-estrogenic properties, muscle hardening, fat oxidation enhancement, and androgen receptor binding without aromatization or water retention. Short-ester engineering facilitates frequent injection frequency maintaining stable plasma concentrations ideal for pre-contest cutting applications spanning 6-8 week cycles with pronounced vascularity and density gains.​

Product Specifications

Injectable solution furnishes 100mg/ml Drostanolone Propionate across 10ml multi-dose capacity utilizing pharmaceutical-grade carrier oil matrix with benzyl alcohol preservation. Sterile filtration deployment through 0.22μ pre-filled rubber-stoppered vial incorporating aluminum seal crimp and flip-top security mechanism. Vial documentation enumerates concentration certification, aggregate volume quantification, sequential lot designation, fabrication temporal reference, and projected pharmacotherapeutic viability timeline.​

Quality Control & Testing Standards

Odin Pharma institutes quantitative chromatographic profiling protocols establishing drostanolone concentration conformance alongside pharmacopeial sterility assurance profiling, endotoxin quantification below 0.5 EU/ml, and preservative system efficacy analysis per established monographs. Precursor qualification precedes esterification via third-party certification while terminal injectable integrity validation incorporates randomized composite sampling. Serialization-linked analytical certification facilitates authenticity adjudication infrastructure.​

Intended Use & Market Positioning

Odin Pharma directs Mast P 100mg/ml 10ml presentation toward advanced clientele executing cutting protocols requiring muscle preservation and definition through 300-700mg weekly injections over 6-8 week cycles. Short-ester configuration enables rapid physiological response combining enhanced vascularity, fat metabolism acceleration, and physique refinement without acne exacerbation beyond predisposed individuals.​

Packaging, Storage & Handling

Primary amber glass vial consolidation within protective secondary enclosure integrates dosage authentication cartography, rubber septum penetration verification, flip-top intrusion detection engineering, and microenvironmental sequestration specifications. Preservation ordinance prescribes thermal confinement 15-25°C within dark, dry repositories mitigating sedimentation and oxidative degradation. Protocol mandates crimp seal continuity validation preceding restricted-access conservation.​

Purchasing & Availability Information

Mast P 100mg/ml 10ml by Odin Pharma sustains perpetual standing inventory across credentialed electronic transaction architectures with redundant warehouse positioning. Transaction orchestration fuses end-to-end cryptographic financial pathway processing, transit obfuscation enclosure protocols, and premium parcel acceleration networks. Institutional acquisition contingents unlock progressive volumetric economic calibration predicated upon eligibility verification.​

Legal & Regulatory Disclaimer

Acquisition principals assume unqualified fiduciary accountability for statutory conformity spanning procurement entitlement, possession legitimacy, cross-jurisdictional conveyance authorization, and application permissions pursuant to controlling federal, state, municipal ordinance hierarchies. Odin Pharma commercializes Mast P 100 exclusively as parametrically-declared bulk active pharmaceutical matrix for research; no attestations encompass therapeutic protocol substitution or physiological trajectory forecasting. Documentation constitutes commercial-informational reference exclusively.​